Orally disintegrating tablets (ODTs) are getting popularity over conventional tablets due totheir convenience in administration and suitability for patients having dysphagia (difficulty in swallowing). There is an increasing demand for more patient compliant dosage form and a novel method is the development orally disintegrating tablets which dissolve or disintegrates instantly on the patient tongue or buccal mucosa. It is suited for tablets undergoing high first pass metabolism and is used for improving bioavailability with reducing dosing frequency to minimize side effect and make it more cost effective. Zolmitriptan is a selective serotonin receptor agonist .Zolmitriptan , the absolute bioavailability is only approximately 40% due to extensive hepatic first pass metabolism (CYP1A2-mediated). Hence the main objective of the study was to formulate oral disintegrating tablets of Zolmitriptan to achieve a better dissolution rate and further improving the bioavailability of the drug. Orally disintegrating tablets prepared by direct compression and using Supertab11SD, Avicel PH 102, Crospovidone, Ac- Di-Sol, Sodium starch glycolate, Aspartame , Magnesium stearate were prepared and evaluated for the precompression parameters such as bulk density, compressibility, angle of repose etc. The prepared batches of tablets were evaluated for hardness, weight variation, friability, disintegration time and in-vitro dissolution profile and found satisfactory. Among the three groups, F9 Formulation as the best formulation and showed maximum dissolution rate with drug release.
